ReviR Therapeutics Doses First Patient in RTX-117 Phase 1 Trial Following Dual U.S. and China IND Clearances

03 March 2026 | News

AI-driven biotech advances clinical development of RNA-modulating therapy targeting rare neurological diseases Charcot-Marie-Tooth and Vanishing White Matter disease.

Subscribe to our newsletter

Monthly digest of what's new and exciting from us.

We'll never share your email with anyone else.